This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Frasci, G. Articles by Comella, G. Search for Related Content PubMed PubMed Citation Articles by Frasci, G. Articles by Comella, G. Social Bookmarking                            What's this?

Cisplatin, Gemcitabine, and Paclitaxel in Locally Advanced or Metastatic Non–Small-Cell Lung Cancer: A Phase I-II Study

From the Southern Italy Cooperative Oncology Group, National Tumor Institute of Naples, Naples, Italy.

Address reprint requests to Dr. Giuseppe Frasci, Division of Medical Oncology A, via M. Semmola 80131, Naples, Italy; email gifrasei{at}sirio-oncology.it

PURPOSE: Because both cisplatin-paclitaxel and cisplatin-gemcitabine combinations are generally considered to be among the most active regimens in non–small-cell lung cancer (NSCLC) patients, this study aimed to determine the maximum-tolerated dose (MTD) of paclitaxel when combined with fixed doses of cisplatin and gemcitabine in advanced NSCLC patients and aimed to define the therapeutic activity of this new regimen.

PATIENTS AND METHODS: From October 1996 to September 1998, 75 patients with stage IIIB-IV NSCLC, who were either chemotherapy-naive (65 patients) or who had been pretreated (10 patients), received fixed doses of cisplatin (50 mg/m²) and gemcitabine (1,000 mg/m²) and escalating doses of paclitaxel in a 1-hour infusion, all on days 1 and 8, every 3 weeks.

RESULTS: Five different paclitaxel doses were tested, for a total of 275 cycles delivered. The escalation was stopped at the paclitaxel dose of 75 mg/m² in pretreated patients, whereas it continued to 150 mg/m² in chemotherapy-naive patients. A total of 65 chemotherapy-naive patients were treated. A paclitaxel dose of 125 mg/m² was recommended for phase II, and a total of 39 patients were treated at this level, for a total of 158 cycles delivered. No treatment-related deaths occurred. Five patients were hospitalized because of sepsis, and packed RBC transfusion was required in 13 patients. Grade 4 neutropenia and thrombocytopenia occurred in 23 (31%) and eight (11%) patients, respectively. Overall, 74 of the 75 patients were assessable for response. Four complete (CR) and 38 partial (PR) responses were recorded, for an overall response rate (ORR) of 57%. Three of the ten pretreated patients achieved a PR, compared with four CRs and 35 PRs in the 64 chemotherapy-naive patients (ORR, 61%). Thirty-eight of 39 patients included in phase II were assessable for response and quality of life (QOL) (one patient's disease was not measurable). Two CRs and 24 PRs were recorded in this group, for an ORR of 68% (95% confidence interval, 51% to 82%). The QOL score improved in 27 of 38 (71%) patients. The median survival time was 15 months in the 65 chemotherapy-naive patients, but it had not yet been reached in the 39 patients included in phase II, for whom the 1-year projected survival was 70%.

CONCLUSION: The cisplatin-gemcitabine-paclitaxel combination is a feasible and well-tolerated approach in advanced NSCLC patients. Both a major response and a QOL improvement can be obtained in a high proportion of patients, with a median survival time exceeding 1 year. A phase III trial comparing this combination with other effective regimens is under way.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				P Comella, G Filippelli, G De Cataldis, B Massidda, G Frasci, L Maiorino, C Putzu, S Mancarella, S Palmeri, R Cioffi, et al. Efficacy of the combination of cisplatin with either gemcitabine and vinorelbine or gemcitabine and paclitaxel in the treatment of locally advanced or metastatic non-small-cell lung cancer: a phase III randomised trial of the Southern Italy Cooperative Oncology Group (SICOG 0101) Ann. Onc., February 1, 2007; 18(2): 324 - 330. [Abstract] [Full Text] [PDF]

				G. P. Stathopoulos, M. Veslemes, N. Georgatou, D. Antoniou, P. Giamboudakis, K. Katis, D. Tsavdaridis, S. K. Rigatos, I. Dimitroulis, S. Bastani, et al. Front-line paclitaxel-vinorelbine versus paclitaxel-carboplatin in patients with advanced non-small-cell lung cancer: a randomized phase III trial Ann. Onc., July 1, 2004; 15(7): 1048 - 1055. [Abstract] [Full Text] [PDF]

				A. Spira and D. S. Ettinger Multidisciplinary Management of Lung Cancer N. Engl. J. Med., January 22, 2004; 350(4): 379 - 392. [Full Text] [PDF]

				V. Lorusso, E. Crucitta, N. Panza, N. Silvestris, M. Guida, F. Carpagnano, S. Mancarella, D. Sambiasi, and M. De Lena Phase I/II study of paclitaxel, gemcitabine and vinorelbine as first-line chemotherapy of non-small-cell lung cancer Ann. Onc., December 1, 2002; 13(12): 1862 - 1867. [Abstract] [Full Text] [PDF]

				J. D. Hainsworth, J. R. Gray, L. H. Morrissey, L. A. Kalman, J. K. Hon, and F. A. Greco Long-Term Follow-Up of Patients Treated With Paclitaxel/Carboplatin-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer: Sequential Phase II Trials of the Minnie Pearl Cancer Research Network J. Clin. Oncol., July 1, 2002; 20(13): 2937 - 2942. [Abstract] [Full Text] [PDF]

				A. Bottomley The Cancer Patient and Quality of Life Oncologist, April 1, 2002; 7(2): 120 - 125. [Abstract] [Full Text] [PDF]